Editorial Expression of Concern: Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma (World J Urol, (2016), 34, (561-567), 10.1007/s00345-015-1656-7);Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma

World Journal of Urology

Volumn 34, Issue 4, 2016, Pages 561-567

  Cai, Chen ^a   Xu, Yi Fan ^a   Wu, Zhen Jie ^b   Dong, Qin ^c   Li, Min Yu ^a   Olson, Jason C ^d   Rabinowitz, Yaron M ^d   Wang, Lin Hui ^b   Sun, Yinghao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Shanghai Corps Hospital   (China)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Renal cell carcinoma; Tim 3; Tumor infiltrating lymphocytes

Indexed keywords

HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; RNA;

BIOSYNTHESIS; CANCER STAGING; CARCINOMA, RENAL CELL; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY; KIDNEY NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA, RENAL CELL; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, NEOPLASM;

EID: 84961218240     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-023-04293-3     Document Type: Erratum

References (22)

1. Ljungberg B (2013) The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. Curr Urol Rep 14:19–25
2. Sircar K, Rao P, Jonasch E, Monzon FA, Tamboli P (2013) Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer 32:303–311
3. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H et al (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415:536–541
4. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX et al (2003) Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 4:1093–1101
5. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A et al (2003) Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 4:1102–1110
6. Wang Y, Yang P, Li B, Zhou H, Huang X et al (2006) Expression of Tim-3 is transiently increased before development of anterior chamber-associated immune deviation. Ocul Immunol Inflamm 14:151–156
7. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A et al (2008) Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 181:7660–7669
8. Nakae S, Iikura M, Suto H, Akiba H, Umetsu DT et al (2007) TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood 110:2565–2568
9. Kearley J, McMillan SJ, Lloyd CM (2007) Th2-driven, allergen-induced airway inflammation is reduced after treatment with anti-Tim-3 antibody in vivo. J Exp Med 204:1289–1294
10. Koguchi K, Anderson DE, Yang L, O’Connor KC, Kuchroo VK et al (2006) Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med 203:1413–1418
11. Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A et al (2007) T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity 26:311–321
12. Frisancho-Kiss S, Nyland JF, Davis SE, Barrett MA, Gatewood SJ et al (2006) Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol 176:6411–6415
13. Kwong BY, Roberts SJ, Silberzahn T, Filler RB, Neustadter JH et al (2010) Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis. J Invest Dermatol 130:1726–1736
14. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M et al (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117:4501–4510
15. Anderson AC (2012) Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 24:213–216
16. Cai C, Wang L, Wu Z, Li M, Chen W et al (2012) T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and renal cell carcinoma. DNA Cell Biol 31:1285–1289
17. Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K et al (2015) The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res. doi:10.1158/2326-6066
18. Amancha PK, Hong JJ, Ansari AA, Villinger F (2015) Up-regulation of Tim-3 on T cells during acute simian immunodeficiency virus infection and on antigen specific responders. AIDS 29:531–536
19. Golden-Mason L, Waasdorp Hurtado CE, Cheng L, Rosen HR (2015) Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3. Clin Immunol 158:114–125
20. Li M, Ablan SD, Miao C, Zheng YM, Fuller MS et al (2014) TIM-family proteins inhibit HIV-1 release. Proc Natl Acad Sci USA 111:E3699–E3707
21. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR et al (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205:2763–2779
22. Haddad AQ, Margulis V (2015) Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol 12:253–262